drugset

drugset / Trial / NCT00748007

Efficacy of Rivastigmine in Patients With Down Syndrome

NCT00748007 ↗

Completed 14 enrolled National Taiwan University Hospital

RandomizedCrossoverDouble-blindTreatment

Summary

This study is to understand the efficacy on language and cognitive function in Down syndrome patients who take Rivastigmine.

Timeline

Start: 2008-01
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivastigmine	Small molecule	1.5 mg	—

Indications